Regeneron stock hits a 52-week high as Q2 revenue jumps
Published on 09/02/2026 at 20:15 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Regeneron Pharmaceuticals stock (US75886F1075) hit a 52-week high at USD 847.60 on September 2, 2026, and last traded at USD 847.19, with a market capitalization of USD 82.3 billion. The move followed a Q2 2026 update that showed revenue up 17 percent to USD 4.29 billion and non-GAAP EPS of USD 14.29.
Q2 figures set the tone
According to Investing.com, the latest quarterly results were driven by Dupixent, Eylea HD and Libtayo. The report said Dupixent global sales reached USD 6.0 billion, up 38 percent year over year, which helped lift sentiment around the shares.
The same update put Regeneron on a stronger footing than the prior year, with Q2 2026 revenue rising 16.7 percent to USD 4.29 billion and adjusted EPS at USD 14.29. That is a concrete beat-and-grow profile, not just a chart story.
Market cap near USD 82 billion
Barchart valued the company at USD 82.3 billion and said REGN had risen 41.9 percent over the past 52 weeks. It also noted that the stock traded 37.1 percent below its 52-week high of USD 847 recorded on August 21, before this latest push back to the top.
For investors, the combination of a 52-week high, a USD 82.3 billion market value and a 41.9 percent 52-week gain is the main market signal today. The stock is no longer just reacting to one quarter; it is pricing a fuller earnings and product mix.
Regeneron revenue and margin drivers
Regeneron stock is now being judged by whether Dupixent, Eylea HD and Libtayo can keep translating sales momentum into higher earnings.
Dupixent stays central
Dupixent remains the clearest product driver in the update, with global sales of USD 6.0 billion in Q2 2026 and growth of 38 percent. That makes the allergy and inflammation franchise the most visible single lever behind the stock re-rating.
Price and venue
Regeneron stock closed at USD 847.19 on September 2, 2026, after touching USD 847.60, with the quote reflecting Nasdaq trading in USD. The 52-week high and the Q2 2026 beat now sit at the center of the near-term equity story.
Regeneron key data
- Company: Regeneron Pharmaceuticals, Inc.
- ISIN: US75886F1075
- Ticker: REGN
- Trading venue: Nasdaq
- Price (as of September 2, 2026): USD 847.19
- Market capitalization: USD 82.3 billion (as of September 2, 2026)
- Sector / Industry: Health Care / Biotechnology
- Index membership: S&P 500
